|
1
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLC strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bruix J, Qin S, Merle P, Granito A, Huang
YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al:
Regorafenib for patients with hepatocellular carcinoma who
progressed on sorafenib treatment (RESORCE): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66.
2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Abou-Alfa GK, Meyer T, Cheng AL,
El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park
JW, et al: Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 379:54–63. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle
PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, et al:
Ramucirumab after sorafenib in patients with advanced
hepatocellular carcinoma and increased α-fetoprotein concentrations
(REACH-2): A randomised, double-blind, placebo-controlled, phase 3
trial. Lancet Oncol. 20:282–296. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Abou-Alfa GK, Lau G, Kudo M, Chan SL,
Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV and De
Toni E: for the HIMALAYA Investigators. Tremelimumab plus
Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid.
1:2022.
|
|
9
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rimola J, Da Fonseca LG, Sapena V, Perelló
C, Guerrero A, Simó MT, Pons M, De La Torre-Aláez M, Márquez L,
Calleja JL, et al: Radiological response to nivolumab in patients
with hepatocellular carcinoma: A multicenter analysis of real-life
practice. Eur J Radiol. 135(109484)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kolamunnage-Dona R, Berhane S, Potts H,
Williams EH, Tanner J, Janowitz T, Hoare M and Johnson P: Sorafenib
is associated with a reduced rate of tumour growth and liver
function deterioration in HCV-induced hepatocellular carcinoma. J
Hepatol. 75:879–887. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bruix J, da Fonseca LG and Reig M:
Insights into the success and failure of systemic therapy for
hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol.
16:617–630. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899.
2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Vesely MD and Schreiber RD: Cancer
immunoediting: Antigens, mechanisms, and implications to cancer
immunotherapy. Ann N Y Acad Sci. 1284:1–5. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Koebel CM, Vermi W, Swann JB, Zerafa N,
Rodig SJ, Old LJ, Smyth MJ and Schreiber RD: Adaptive immunity
maintains occult cancer in an equilibrium state. Nature.
450:903–907. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Templeton AJ, McNamara MG, Šeruga B,
Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106(dju124)2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Scheiner B, Pomej K, Kirstein MM, Hucke F,
Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J,
Fründt TW, et al: Prognosis of patients with hepatocellular
carcinoma treated with immunotherapy-development and validation of
the CRAFITY score. J Hepatol. 76:353–363. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Luen SJ, Savas P, Fox SB, Salgado R and
Loi S: Tumour-infiltrating lymphocytes and the emerging role of
immunotherapy in breast cancer. Pathology. 49:141–155.
2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
da Fonseca LG, Barroso-Sousa R, Bento Ada
S, Blanco BP, Valente GL, Pfiffer TE, Hoff PM and Sabbaga J:
Pre-treatment neutrophil-to-lymphocyte ratio affects survival in
patients with advanced hepatocellular carcinoma treated with
sorafenib. Med Oncol. 31(264)2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Bruix J, Cheng AL, Meinhardt G, Nakajima
K, De Sanctis Y and Llovet J: Prognostic factors and predictors of
sorafenib benefit in patients with hepatocellular carcinoma:
Analysis of two phase III studies. J Hepatol. 67:999–1008.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
European Association for the Study of the
Liver. Electronic address: simpleeasloffice@easloffice.eu;
European Association for the Study of the Liver. EASL clinical
practice guidelines: Management of hepatocellular carcinoma. J
Hepatol. 69:182–236. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z,
Chen EB, Fan J, Cao Y, Dai Z and Zhou J: Tumor-Associated
neutrophils recruit macrophages and T-Regulatory cells to promote
progression of hepatocellular carcinoma and resistance to
sorafenib. Gastroenterology. 150:1646–1658.e17. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Romero AI, Chaput N, Poirier-Colame V,
Rusakiewicz S, Jacquelot N, Chaba K, Mortier E, Jacques Y,
Caillat-Zucman S, Flament C, et al: Regulation of CD4(+)NKG2D(+)
Th1 cells in patients with metastatic melanoma treated with
sorafenib: Role of IL-15Rα and NKG2D triggering. Cancer Res.
74:68–80. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mathew NR, Baumgartner F, Braun L,
O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S,
Apostolova P, et al: Sorafenib promotes graft-versus-leukemia
activity in mice and humans through IL-15 production in
FLT3-ITD-mutant leukemia cells. Nat Med. 24:282–291.
2018.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Hepatocellular carcinoma. Nat Rev Dis
Prim. 7(7)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gonzalez H, Hagerling C and Werb Z: Roles
of the immune system in cancer: From tumor initiation to metastatic
progression. Genes Dev. 32:1267–1284. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hanahan D and Coussens LM: Accessories to
the crime: Functions of cells recruited to the tumor
microenvironment. Cancer Cell. 21:309–322. 2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Masopust D and Schenkel JM: The
integration of T cell migration, differentiation and function. Nat
Rev Immunol. 13:309–320. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Szczerba BM, Castro-Giner F, Vetter M,
Krol I, Gkountela S, Landin J, Scheidmann MC, Donato C, Scherrer R,
Singer J, et al: Neutrophils escort circulating tumour cells to
enable cell cycle progression. Nature. 566:553–557. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wu WC, Sun HW, Chen HT, Liang J, Yu XJ, Wu
C, Wang Z and Zheng L: Circulating hematopoietic stem and
progenitor cells are myeloid-biased in cancer patients. Proc Natl
Acad Sci USA. 111:4221–4226. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Almand B, Clark JI, Nikitina E, van Beynen
J, English NR, Knight SC, Carbone DP and Gabrilovich DI: Increased
production of immature myeloid cells in cancer patients: A
mechanism of immunosuppression in cancer. J Immunol. 166:678–689.
2001.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Martin D, Rödel F, Winkelmann R, Balermpas
P, Rödel C and Fokas E: Peripheral leukocytosis is inversely
correlated with intratumoral CD8+ T-Cell infiltration
and associated with worse outcome after chemoradiotherapy in anal
cancer. Front Immunol. 8(1225)2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Dushyanthen S, Beavis PA, Savas P, Teo ZL,
Zhou C, Mansour M, Darcy PK and Loi S: Relevance of
tumor-infiltrating lymphocytes in breast cancer. BMC Med.
13(202)2015.PubMed/NCBI View Article : Google Scholar
|
